Episode Details
Back to Episodes
Daily Roundup | Enhertu Delays Lung Cancer Progression, Survival Benefit Unproven
Season 1
Published 4 days, 3 hours ago
Description
Enhertu delayed lung cancer progression in a Phase 3 trial, but immature survival results and fatal lung toxicity complicate the first-line case. Definium reports a second Phase 3 anxiety-study win for DT120, while new ivonescimab results quantify a survival benefit previously announced. We also cover Sanofi's proposed Cheplapharm transaction, Cellectis's gene-editing pivot, Corbus's oral obesity candidate and regulatory updates from Amgen and Telix. This is the September 14 edition, released September 15.
Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.